Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Treatment
Share your love
Eyenovia Pediatric Myopia Trial Falls Short
Eyenovia has announced that its Phase 3 CHAPERONE study, aimed at treating pediatric progressive myopia, failed to meet its primary endpoint. The trial evaluated the company’s proprietary drug-device combination using low-dose atropine delivered via the Optejet platform. A review by…
Cequa Shows Positive Phase 4 Results for Dry Eye
Sun Pharmaceutical has shared new Phase 4 clinical trial data, showcasing the efficacy of Cequa (cyclosporine ophthalmic solution) 0.09% in treating dry eye disease (DED). The results reveal that Cequa provides sustained improvements in patients whose symptoms were inadequately managed…
MediPrint Announces Positive Results for Glaucoma Lens
MediPrint Ophthalmics has revealed positive findings from its Phase 2b clinical trial for LL-BMT1, a 3D-printed, drug-eluting contact lens designed to treat mild to moderate glaucoma. These results, presented by Ian Ben Gaddie, OD, FAAO, at the American Academy of…
Atsena & Nippon Shinyaku Partner on ATSN-101
Atsena Therapeutics, Inc. and Nippon Shinyaku Co., Ltd. have entered an exclusive licensing agreement to advance and commercialize ATSN-101, an investigational gene therapy for Leber congenital amaurosis type 1 (LCA1), in both the United States and Japan. ATSN-101 is designed…
Harrow Gains Medicare Part D Access for Vevye in 2025
Harrow has announced that its dry eye disease treatment, Vevye, will be added to the formularies of key Medicare Part D plan sponsors starting January 1, 2025. Major plan sponsors including Express Scripts, Cigna, Kaiser Permanente, and CVS Caremark, which…
Top 15 International Ophthalmology Congresses in 2024
As the field of ophthalmology continues to advance, a plethora of international congresses offer opportunities for professionals to explore the latest innovations, share insights, and foster collaborations. Here is a comprehensive list of the top 15 international ophthalmology conferences scheduled…
What Is Ophthalmia Neonatorum? | OBN
Ophthalmia neonatorum, also known as neonatal conjunctivitis, is an inflammation of the conjunctiva (the clear membrane covering the white part of the eye) that occurs in newborns. It is a serious condition that can lead to blindness if left untreated.…
Ocular Therapeutix Enrolls First Patient in Phase 3 Wet AMD Study
Ocular Therapeutix announced that the first patients have been enrolled in its Phase 3 SOL-R clinical trial. This study aims to assess the repeat dosing of AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI) for treating wet age-related macular degeneration…
Eyenovia and SGN Nanopharma to Develop Dry Eye Treatment
Eyenovia and SGN Nanopharma have announced a new collaboration to develop a treatment for chronic dry eye disease. Eyenovia, known for its two FDA-approved products and a late-stage asset in pediatric progressive myopia, will work with SGN Nanopharma to develop…
Novaliq’s Vevizye® Receives Positive CHMP Opinion for DED
Novaliq announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion recommending the granting of a marketing authorization for Vevizye® in the European Union. This therapy is designed to treat moderate…